Influenza Vaccine Effectiveness in Children at the Emergency Department during the 2018-2019 Season: the First Season School-aged Children Were Included in the Korean Influenza National Immunization Program

被引:1
|
作者
Yoon, Yoonsun [1 ]
Choi, Joon-sik [2 ]
Park, MiRan [1 ]
Cho, Hyun [3 ]
Park, Minsu [4 ]
Huh, Hee Jae [5 ]
Kim, Yae-Jean [1 ]
Son, Meong Hi [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pediat, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea
[2] Yonsei Univ Med, Yongin Severance Hosp, Dept Hosp Med, Yongin, South Korea
[3] Samsung Med Ctr, Stat & Data Ctr, Seoul, South Korea
[4] Keimyung Univ, Dept Stat, Daegu, South Korea
[5] Sungkyunkwan Univ, Samsung Med Ctr, Dept Lab Med & Genet, Sch Med, Seoul, South Korea
关键词
Influenza; Vaccine Effectiveness; Children; National Immunization Program; TEST-NEGATIVE DESIGN; UNITED-STATES;
D O I
10.3346/jkms.2021.36.e71
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For the 2018-2019 season, the national influenza immunization program expanded to cover children aged from 6 months to 12 years in Korea. This study aimed to analyze vaccine effectiveness (VE) against influenza in children visiting the pediatric emergency room at a tertiary hospital during the 2018-2019 season. Methods: Patients tested for influenza antigens from October 1st 2018 to May 31st 2019 at the pediatric emergency room of Samsung Medical Center were included. Patients' influenza antigen test results, influenza vaccination history, and underlying medical conditions were reviewed retrospectively. VE was estimated from the test-negative design study. Results: Among the 2,901 visits with influenza test results 1,692 visits of 1,417 patients were included for analysis. Among these 1,417 patients, 285 (20.1%) were positive (influenza A, n = 211, 74.0%; influenza B, n = 74, 26.0%). The VE in all patients was 36.4% (95% confidence interval [CI], 13.9 to 53.1). The VE for influenza A was 37.6% (95% CI, 12.6 to 55.5) and VE for influenza B was 24.0% (-38.5 to 58.3). The VE in the age group 6 months to 12 years was significant with a value of 35.6% (95% CI, 10.5 to 53.7); it was not statistically significant in the age group 13 to 18 years. In a multivariate logistic regression model, patients who received an influenza vaccination were less likely to get influenza infection (OR, 0.6; 95% CI, 0.4 to 0.8; P= 0.001), with significant confounding factors such as age group 13 to 18 years (OR, 0.5; 95% CI, 0.3 to 0.8; P= 0.003) and underlying hematology-oncology disease (OR, 0.3; 95% CI, 0.1 to 0.6; P= 0.002). conclusion: We report moderate effectiveness of influenza vaccination in previously healthy children aged from 6 months to 12 years in the 2018-2019 season.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Factors Associated With Receipt of 2009 Pandemic Influenza A (H1N1) Monovalent and Seasonal Influenza Vaccination Among School-Aged Children: Maricopa County, Arizona, 2009-2010 Influenza Season
    Baty, Steven A.
    Ayala, Aurimar
    Odish, Mazen
    Cadwell, Betsy L.
    Schumacher, Mare
    Sunenshine, Rebecca H.
    JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE, 2013, 19 (05): : 436 - 443
  • [42] Relative Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine in Preventing Cardiorespiratory Hospitalizations in Adults Aged 18-64 Years During the 2019-2020 US Influenza Season
    Imran, Mahrukh
    Puig-Barbera, Juan
    Ortiz, Justin R.
    Lopez-Gonzalez, Lorena
    Dean, Alex
    Bonafede, Machaon
    Haag, Mendel
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (07):
  • [43] Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network
    Adams, Katherine
    Weber, Zachary A.
    Yang, Duck-Hye
    Klein, Nicola P.
    Desilva, Malini B.
    Dascomb, Kristin
    Irving, Stephanie A.
    Naleway, Allison L.
    Rao, Suchitra
    Gaglani, Manjusha
    Flannery, Brendan
    Garg, Shikha
    Kharbanda, Anupam B.
    Grannis, Shaun J.
    Ong, Toan C.
    Embi, Peter J.
    Natarajan, Karthik
    Fireman, Bruce
    Zerbo, Ousseny
    Goddard, Kristin
    Timbol, Julius
    Hansen, John R.
    Grisel, Nancy
    Arndorfer, Julie
    Ball, Sarah W.
    Dunne, Margaret M.
    Kirshner, Lindsey
    Chung, Jessie R.
    Tenforde, Mark W.
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (03) : 746 - 755
  • [44] Relative Effectiveness of Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children and Adolescents in the United States During the 2019-2020 Influenza Season
    Imran, Mahrukh
    Ortiz, Justin R.
    McLean, Huong Q.
    Fisher, Lauren
    O'Brien, Dan
    Bonafede, Machaon
    Mansi, James A.
    Boikos, Constantina
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2022, 41 (09) : 769 - 774
  • [45] Effectiveness of trivalent inactivated influenza vaccines in children during 2017-2018 season in Korea: Comparison of test-negative analysis by rapid and RT-PCR influenza tests
    Sohn, Young Joo
    Choi, Jae Hong
    Choi, Youn Young
    Choe, Young June
    Kim, Kyungmin
    Kim, Ye Kyung
    Ahn, Bin
    Song, Seung Ha
    Han, Mi Seon
    Park, Ji Young
    Lee, Joon Kee
    Choi, Eun Hwa
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 99 : 199 - 203
  • [46] Evaluation of the field-protective effectiveness of seasonal influenza vaccine among Korean children aged < 5 years during the 2014-2015 and 2015-2016 influenza seasons: a cohort study
    Kang, Young Kyung
    Oh, Hea Lin
    Lim, Jung Sub
    Lee, Jun Ah
    Kim, Yun Kyung
    Eun, Byung Wook
    Jo, Dae Sun
    Kim, Dong Ho
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (02) : 481 - 486
  • [47] Sustained Within-season Vaccine Effectiveness Against Influenza-associated Hospitalization in Children: Evidence From the New Vaccine Surveillance Network, 2015-2016 Through 2019-2020
    Sahni, Leila C.
    Naioti, Eric A.
    Olson, Samantha M.
    Campbell, Angela P.
    Michaels, Marian G.
    Williams, John, V
    Staat, Mary Allen
    Schlaudecker, Elizabeth P.
    McNeal, Monica M.
    Halasa, Natasha B.
    Stewart, Laura S.
    Chappell, James D.
    Englund, Janet A.
    Klein, Eileen J.
    Szilagyi, Peter G.
    Weinberg, Geoffrey A.
    Harrison, Christopher J.
    Selvarangan, Rangaraj
    Schuster, Jennifer E.
    Azimi, Parvin H.
    Singer, Monica N.
    Avadhanula, Vasanthi
    Piedra, Pedro A.
    Munoz, Flor M.
    Patel, Manish M.
    Boom, Julie A.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1031 - E1039
  • [48] Influenza vaccine effectiveness estimates against influenza A(H3N2) and A(H1N1) pdm09 among children during school-based outbreaks in the 2016-2017 season in Beijing, China
    Zhang, Li
    van der Hoek, Wim
    Krafft, Thomas
    Pilot, Eva
    van Astenc, Liselotte
    Lin, Ge
    Wu, Shuangsheng
    Duan, Wei
    Yang, Peng
    Wang, Quanyi
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (04) : 816 - 822
  • [49] Live-attenuated influenza vaccine effectiveness against hospitalization in children aged 2-6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14-2015/16
    Boddington, Nicki L.
    Mangtani, Punam
    Zhao, Hongxin
    Verlander, Neville Q.
    Ellis, Joanna
    Andrews, Nick
    Pebody, Richard G.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (05) : 897 - 905
  • [50] Reduction of influenza A(H3N2)-associated symptoms by influenza vaccination in school aged-children during the 2014-2015 winter season dominated by mismatched H3N2 viruses
    Duan, Wei
    Zhang, Li
    Wu, Shuangsheng
    Ma, Chunna
    Sun, Ying
    Zhang, Man
    Zhang, Yi
    Zhang, Xingxing
    Wang, Quanyi
    Yang, Peng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) : 1031 - 1034